Health deep-tech Mesh Bio raised $3.5 M Series A funding from VC firm East Ventures
The Southeast Asia-focused venture capital firm East Ventures led the $3.5 million Series A financing round led by Singapore-based health deep tech startup Mesh Bio.
According to a statement from Mesh Bio, Elev8, Seed Capitals, and other current investors have also participated in this round of investment.
The funding, according to the statement, will enable Mesh Bio to expand the deployment of these solutions throughout Southeast Asia, primarily Indonesia and the Philippines, as well as Hong Kong, by providing its digital twin technologies to healthcare providers.
Notably, Mesh Bio received historic regulatory approval three months prior to this new investment, and one of its digital twin technologies is the subject of an implementation pilot with public health systems in Singapore. This represents a significant opportunity to improve patient outcomes related to chronic diseases.
The company was given permission by Singapore’s Health Sciences Authority (HSA) in October 2023 to sell its HealthVector® Diabetes as a Software Medical Device (SaMD).
Tan Tock Seng Hospital (TTSH), Singapore General Hospital (SGH), and a few polyclinics are now participating in an implementation pilot program to test the clinical adoption of HealthVector® Diabetes.
“We are excited to announce the closure of our Series A funding, this pivotal step empowers us to expand our digital health solutions for chronic disease management in Southeast Asia,” said Dr. Andrew Wu, Co-Founder and Chief Executive Officer of Mesh Bio.
“Southeast Asia presents myriad unmet healthcare needs, and our focus is to address these gaps effectively,
“With East Ventures’ support, we are poised to support the rapid digital transformation of healthcare systems in this region to improve lives. We deeply appreciate their belief in our mission and commitment to healthcare innovation,” he added.
A digital health startup called Mesh Bio is committed to solving the problems associated with care delivery as well as the increasing clinical burden of metabolic diseases worldwide as a result of population aging.
Wu and Arsen Batagov (Co-Founder and Chief Technology Officer) founded the company in 2018.
One of its earlier funding rounds, which took place in October 2021, was a $1.8 million seed round.
The statement claims that a greater number of general practitioners—who do not have specialized training in endocrinology—are managing patients with chronic diseases as a result of Southeast Asia’s high prevalence of chronic illnesses, which range from diabetes to heart disease.
Mesh Bio offers state-of-the-art digital solutions to assist medical professionals in managing patients.
